Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. The company is based in New York, New York. Akari Therapeutics, Plc is a subsidiary of RPC Pharma Limited.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone44-20-8004-0270
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/20/2019 (Estimated)
OptionableNot Optionable
Akari Therapeutics (NASDAQ:AKTX) Frequently Asked Questions
What is Akari Therapeutics' stock symbol?
Akari Therapeutics trades on the NASDAQ under the ticker symbol "AKTX."
When is Akari Therapeutics' next earnings date?
What price target have analysts set for AKTX?
2 brokerages have issued 1-year price objectives for Akari Therapeutics' shares. Their forecasts range from $3.00 to $8.00. On average, they expect Akari Therapeutics' share price to reach $5.50 in the next year. This suggests a possible upside of 15.3% from the stock's current price. View Analyst Price Targets for Akari Therapeutics.
What is the consensus analysts' recommendation for Akari Therapeutics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akari Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akari Therapeutics.
Has Akari Therapeutics been receiving favorable news coverage?
News headlines about AKTX stock have been trending somewhat positive on Tuesday, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Akari Therapeutics earned a coverage optimism score of 1.3 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days.
Who are some of Akari Therapeutics' key competitors?
Some companies that are related to Akari Therapeutics include Constellation Pharmaceuticals (CNST), Seres Therapeutics (MCRB), Protagonist Therapeutics (PTGX), Edge Therapeutics (EDGE), BIOFRONTERA AG/ADR (BFRA), Neptune Wellness Solutions (NEPT), TapImmune (MRKR), Xeris Pharmaceuticals (XERS), Calithera Biosciences (CALA), Dova Pharmaceuticals (DOVA), Verastem (VSTM), Tocagen (TOCA), AcelRx Pharmaceuticals (ACRX), Kamada (KMDA) and resTORbio (TORC).
What other stocks do shareholders of Akari Therapeutics own?
Who are Akari Therapeutics' key executives?
Akari Therapeutics' management team includes the folowing people:
- Dr. Ray Prudo, Exec. Chairman (Age 74)
- Mr. Clive Richardson, COO, Director & Interim CEO (Age 54)
- Mr. Dov Elefant, Chief Financial Officer (Age 52)
- Dr. Miles Nunn, Chief Scientific Officer
- Dr. Wynne Weston-Davies MRCS, LRCP, MBBS, FRCS, ECFMG, Medical Director
Who are Akari Therapeutics' major shareholders?
Which institutional investors are buying Akari Therapeutics stock?
How do I buy shares of Akari Therapeutics?
Shares of AKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Akari Therapeutics' stock price today?
One share of AKTX stock can currently be purchased for approximately $4.77.
How big of a company is Akari Therapeutics?
Akari Therapeutics has a market capitalization of $72.79 million. The biopharmaceutical company earns $-35,390,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis.
What is Akari Therapeutics' official website?
How can I contact Akari Therapeutics?
Akari Therapeutics' mailing address is 75/76 WIMPOLE STREE, LONDON X0, W1G 9RT. The biopharmaceutical company can be reached via phone at 44-20-8004-0270 or via email at [email protected]
MarketBeat Community Rating for Akari Therapeutics (NASDAQ AKTX)
MarketBeat's community ratings are surveys of what our community members think about Akari Therapeutics and other stocks. Vote "Outperform" if you believe AKTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
